TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
1-Year Return
18.15%
This Quarter Return
+13.64%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.46B
AUM Growth
+$126M
(+5.4%)
Cap. Flow
-$109M
Cap. Flow
% of AUM
-4.43%
Top 10 Holdings %
Top 10 Hldgs %
40.31%
Holding
213
New
10
Increased
47
Reduced
69
Closed
17
Top Buys
| 1 |
Pfizer
PFE
|
$23.5M |
| 2 |
Merck
MRK
|
$21.2M |
| 3 |
Welltower
WELL
|
$14.9M |
| 4 |
Eli Lilly
LLY
|
$10.2M |
| 5 |
CELG
Celgene Corp
CELG
|
$8.65M |
Top Sells
| 1 |
Biogen
BIIB
|
$19.1M |
| 2 |
Johnson & Johnson
JNJ
|
$18.8M |
| 3 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$16.3M |
| 4 |
AbbVie
ABBV
|
$13.9M |
| 5 |
Thermo Fisher Scientific
TMO
|
$13.5M |
Sector Composition
| 1 | Healthcare | 94.43% |
| 2 | Real Estate | 2.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Edwards Lifesciences
EW
$47.5B
| $10.9M | 0.44% |
170,394
| – | – |
|
52
Zimmer Biomet
ZBH
$20.9B
| $10.2M | 0.41% |
82,044
-9,836
| -11% | -$1.22M |
|
53
Jazz Pharmaceuticals
JAZZ
$7.86B
| $9.65M | 0.39% |
67,471
-47,716
| -41% | -$6.82M |
|
54
FibroGen
FGEN
$48.9M
| $9.55M | 0.39% |
7,030
-1,481
| -17% | -$2.01M |
|
55
Nektar Therapeutics
NKTR
$764M
| $9.53M | 0.39% |
18,912
+12,620
| +201% | +$6.36M |
|
56
Humana
HUM
$37B
| $9.49M | 0.39% |
35,682
-32,805
| -48% | -$8.73M |
|
|
BPMC
57
DELISTED
Blueprint Medicines
BPMC
| $9.26M | 0.38% |
115,720
-9,487
| -8% | -$759K |
|
58
GSK
GSK
$81.5B
| $9.14M | 0.37% |
174,960
| – | – |
|
59
Sabra Healthcare REIT
SBRA
$4.56B
| $9.08M | 0.37% |
466,247
-76,615
| -14% | -$1.49M |
|
60
Ionis Pharmaceuticals
IONS
$9.76B
| $8.91M | 0.36% |
109,720
+26,882
| +32% | +$2.18M |
|
|
ARRY
61
DELISTED
Array Biopharma Inc
ARRY
| $8.88M | 0.36% |
364,166
| – | – |
|
|
XLRN
62
DELISTED
Acceleron Pharma Inc.
XLRN
| $8.77M | 0.36% |
188,388
+17,622
| +10% | +$821K |
|
63
McKesson
MCK
$85.5B
| $8.28M | 0.34% |
70,720
-8,000
| -10% | -$936K |
|
|
MDCO
64
DELISTED
Medicines Co
MDCO
| $8.2M | 0.33% |
293,392
-135,600
| -32% | -$3.79M |
|
65
SPDR S&P Biotech ETF
XBI
$5.39B
| $8.06M | 0.33% |
89,022
-55,402
| -38% | -$5.02M |
|
66
Align Technology
ALGN
$10.1B
| $8.04M | 0.33% |
28,278
-1,582
| -5% | -$450K |
|
67
Sanofi
SNY
$113B
| $7.97M | 0.32% |
179,900
| – | – |
|
68
Dentsply Sirona
XRAY
$2.92B
| $7.76M | 0.32% |
156,521
+30,896
| +25% | +$1.53M |
|
69
Smith & Nephew
SNN
$16.5B
| $7.44M | 0.3% |
185,478
| – | – |
|
70
Esperion Therapeutics
ESPR
$540M
| $7.41M | 0.3% |
184,607
+42,318
| +30% | +$1.7M |
|
71
Sutro Biopharma
STRO
$89.9M
| $7.3M | 0.3% |
641,268
+411,368
| +179% | +$4.69M |
|
72
Alkermes
ALKS
$4.94B
| $7.23M | 0.29% |
198,048
+46,765
| +31% | +$1.71M |
|
73
Ascendis Pharma
ASND
$12.5B
| $7.22M | 0.29% |
61,360
+18,961
| +45% | +$2.23M |
|
74
ResMed
RMD
$40.6B
| $7.17M | 0.29% |
68,974
+10,344
| +18% | +$1.08M |
|
|
PVLA
75
Palvella Therapeutics, Inc. Common Stock
PVLA
$616M
| $6.99M | 0.28% |
26,092
| – | – |
|